Ohio State And Emory Universities Announce Funding For Alzheimer's Research
Ohio State and Emory University are the recipients of support and funding from the Harrington Discovery Institute at UH Case Medical Center and the Alzheimer’s Drug Discovery Foundation. The two institutions are receiving the funding in order to continue research on promising Alzheimer’s treatments. The Alzheimer’s Drug Discovery Foundation will be providing the financial awards, which include a grant of $220,000 to Ohio State and a $101,000 grant to Emory. The Harrington Discovery Institute will provide project management support to the two institutions.
Jonathan Stamler, the director of the Harrington Discovery Institute, released a statement on the selection of the two universities for funding. “Our selection process focuses foremost on the potential of discoveries made by the ADDF Harrington Scholars to slow the progression of Alzheimer’s and improve the quality of life of patients impacted by the disease,” said Stamler. “We are honored to join forces with the ADDF in our mission to bridge the critical gap in funding, enabling the scientific pursuit of many innovative and novel therapies that might otherwise go unexplored.”
Howard Fillit, MD, Executive Director and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation, echoed the Stamler’s sentiments, adding that the critical support given to the two institutions will help speed up drug discovery in the Alzheimer’s field that might not otherwise be possible.
The Harrington Discovery Institute will also be providing access to BioMotiv, a for-profit commercialization company which will help the institutions to advance their discoveries as needs arise in the research process.
Both the Harrington Discovery Institute and the Alzheimer’s Drug Discovery Foundation have a history of supporting Alzheimer’s causes. The organizations choose to fund projects, such as the ones ongoing at Ohio State and Emory, which are promising but are not far enough along or have not generated enough interest to earn funding from pharmaceutical companies or medical investors.